-DOCSTART- -X- O
Inflammatory -X- _ O
responses -X- _ O
contribute -X- _ O
to -X- _ O
the -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
of -X- _ O
severe -X- _ O
influenza. -X- _ O
Current -X- _ O
antiviral -X- _ O
therapy -X- _ O
offers -X- _ O
limited -X- _ O
success -X- _ O
in -X- _ O
treating -X- _ O
severe -X- _ O
influenza -X- _ O
infection -X- _ O
with -X- _ O
both -X- _ O
H1N1 -X- _ O
and -X- _ O
H5N1 -X- _ O
viruses. -X- _ O
We -X- _ O
evaluated -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
a -X- _ O
neuraminidase -X- _ O
inhibitor -X- _ B-Intervention
in -X- _ I-Intervention
combination -X- _ I-Intervention
with -X- _ I-Intervention
immunomodulatory -X- _ I-Intervention
drugs -X- _ I-Intervention
in -X- _ I-Intervention
vitro -X- _ I-Intervention
and -X- _ O
in -X- _ O
a -X- _ O
mouse -X- _ B-Patient
model -X- _ I-Patient
of -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
H1N1 -X- _ I-Patient
infection -X- _ O
by -X- _ O
determining -X- _ O
survival -X- _ O
rate -X- _ O
, -X- _ O
lung -X- _ O
inflammation -X- _ O
markers -X- _ O
and -X- _ O
histopathology. -X- _ O
Sertraline -X- _ B-Outcome
and -X- _ I-Outcome
rolipram -X- _ I-Outcome
significantly -X- _ I-Outcome
improved -X- _ I-Outcome
survival -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
infected -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
lethal -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
H1N1 -X- _ I-Outcome
virus. -X- _ I-Outcome
Prophylactic -X- _ I-Outcome
treatment -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
survival -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
40 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
rolipram -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
30 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
0 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
sertraline -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
100 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
rolipram -X- _ I-Outcome
/ -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
70 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
sertraline -X- _ I-Outcome
/ -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Treatment -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
therapeutic -X- _ I-Outcome
setting -X- _ I-Outcome
( -X- _ I-Outcome
24 -X- _ I-Outcome
h -X- _ I-Outcome
post-infection -X- _ I-Outcome
) -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
80 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
rolipram -X- _ I-Outcome
/ -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
40 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
sertraline -X- _ I-Outcome
/ -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
) -X- _ I-Outcome
survival. -X- _ I-Outcome
Sertraline -X- _ I-Outcome
and -X- _ I-Outcome
rolipram -X- _ I-Outcome
had -X- _ I-Outcome
no -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
virus -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
lung -X- _ I-Outcome
inflammation. -X- _ I-Outcome
A -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
cellular -X- _ I-Outcome
infiltration -X- _ I-Outcome
( -X- _ I-Outcome
10-fold -X- _ I-Outcome
) -X- _ I-Outcome
along -X- _ I-Outcome
with -X- _ I-Outcome
inflammatory -X- _ I-Outcome
cytokines -X- _ I-Outcome
monocyte -X- _ I-Outcome
chemotactic -X- _ I-Outcome
protein-1 -X- _ I-Outcome
( -X- _ I-Outcome
10-fold -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
interleukin-6 -X- _ I-Outcome
( -X- _ I-Outcome
5-fold -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
regulated -X- _ I-Outcome
on -X- _ I-Outcome
activation -X- _ I-Outcome
normal -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
expressed -X- _ I-Outcome
and -X- _ I-Outcome
secreted -X- _ I-Outcome
( -X- _ I-Outcome
5-fold -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
animals -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
combination -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
alone. -X- _ I-Outcome
Lung -X- _ I-Outcome
histopathology -X- _ I-Outcome
of -X- _ I-Outcome
mice -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
combinations -X- _ I-Outcome
revealed -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
consolidation -X- _ I-Outcome
, -X- _ I-Outcome
infiltration -X- _ I-Outcome
and -X- _ I-Outcome
alveolitis -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
alone. -X- _ I-Outcome
Rolipram -X- _ I-Outcome
and -X- _ I-Outcome
sertraline -X- _ I-Outcome
reduced -X- _ I-Outcome
H1N1 -X- _ I-Outcome
virus-induced -X- _ I-Outcome
lung -X- _ I-Outcome
inflammation -X- _ I-Outcome
and -X- _ I-Outcome
mortality. -X- _ I-Outcome
These -X- _ O
data -X- _ O
support -X- _ O
further -X- _ O
development -X- _ O
of -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
for -X- _ O
severe -X- _ O
influenza -X- _ O
. -X- _ O

